Ranibizumab monoclonal antibody fragment (Fab) drug. Targets Vascular endothelial growth factor A (VEGFA) and is indicated for the treatment of age-re

---

Ranibizumab monoclonal antibody fragment (Fab) drug. Targets Vascular endothelial growth factor A (VEGFA) and is indicated for the treatment of age-related macular degeneration (AMD). Closely related to bevacizumab. Generic name and stylized antibody.

---

Size: 9000px × 4582px
Photo credit: © molekuul.be / Alamy / Afripics
License: Royalty Free
Model Released: No

Keywords: age-related, amd, angiogenesis, anti-angiogenic, anti-vegf, antibody, bevacizumab, biological, biosimilar, biotech, biotechnology, degeneration, disease, drug, fab, humour, immunoglobulin, immunology, infusion, injection, inn, intravitreal, intravitreally, mab, macular, monoclonal, nomenclature, peptide, protein, ranibizumab, vitreous, wet